Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.

Article Details

Citation

Sinha N, Sen S

Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.

Eur J Med Chem. 2011 Feb;46(2):618-30. doi: 10.1016/j.ejmech.2010.11.042. Epub 2010 Dec 8.

PubMed ID
21185626 [ View in PubMed
]
Abstract

A QSAR based predictive model of hERG activity in terms of 'global descriptors' has been developed and evaluated. The QSAR was developed by training 77 compounds covering a wide range of activities and was validated based on an external 'test set' of 80 compounds using neural network method. Statistical parameters and examination of enrichment factor indicated the effectiveness of the present model. Randomization test demonstrated the robustness of the model and cross-validation test further validated the QSAR. Domain of applicability test indicated to the high degree of reliability of the predicted results. Satisfactory performance in classifying compounds into 'active' and 'inactive' groups was also obtained. The cases where the QSAR failed, the possible sources of errors have been discussed.

DrugBank Data that Cites this Article

Binding Properties
DrugTargetPropertyMeasurementpHTemperature (°C)
AmiodaroneHERG human cardiac K+ channelIC 50 (nM)1000N/AN/ADetails
AmsacrinePotassium voltage-gated channel subfamily H member 2IC 50 (nM)208.93N/AN/ADetails
AstemizolePotassium voltage-gated channel subfamily H member 2IC 50 (nM)11.48N/AN/ADetails
AzimilidePotassium voltage-gated channel subfamily H member 2IC 50 (nM)562.34N/AN/ADetails
BepridilPotassium voltage-gated channel subfamily H member 2IC 50 (nM)22.91N/AN/ADetails
CarvedilolPotassium voltage-gated channel subfamily H member 2IC 50 (nM)12589.25N/AN/ADetails
ChlorpromazinePotassium voltage-gated channel subfamily H member 2IC 50 (nM)1479.11N/AN/ADetails
CisapridePotassium voltage-gated channel subfamily H member 2IC 50 (nM)6.76N/AN/ADetails
DisopyramidePotassium voltage-gated channel subfamily H member 2IC 50 (nM)91201.08N/AN/ADetails
DoxazosinHERG human cardiac K+ channelIC 50 (nM)588.84N/AN/ADetails
DoxepinPotassium voltage-gated channel subfamily H member 2IC 50 (nM)6456.54N/AN/ADetails
DronedaronePotassium voltage-gated channel subfamily H member 2IC 50 (nM)316.23N/AN/ADetails
FlecainidePotassium voltage-gated channel subfamily H member 2IC 50 (nM)3890.45N/AN/ADetails
FluoxetinePotassium voltage-gated channel subfamily H member 2IC 50 (nM)457.09N/AN/ADetails
HalofantrinePotassium voltage-gated channel subfamily H member 2IC 50 (nM)194.98N/AN/ADetails
IbutilidePotassium voltage-gated channel subfamily H member 2IC 50 (nM)15.14N/AN/ADetails
ImipraminePotassium voltage-gated channel subfamily H member 2IC 50 (nM)3388.44N/AN/ADetails
LoratadinePotassium voltage-gated channel subfamily H member 2IC 50 (nM)173.78N/AN/ADetails
PerhexilinePotassium voltage-gated channel subfamily H member 2IC 50 (nM)7762.47N/AN/ADetails
PimozidePotassium voltage-gated channel subfamily H member 2IC 50 (nM)54.95N/AN/ADetails
PrazosinPotassium voltage-gated channel subfamily H member 2IC 50 (nM)1584.89N/AN/ADetails
ProcainamidePotassium voltage-gated channel subfamily H member 2IC 50 (nM)138038.43N/AN/ADetails
SertindolePotassium voltage-gated channel subfamily H member 2IC 50 (nM)14.79N/AN/ADetails
TamoxifenPotassium voltage-gated channel subfamily H member 2IC 50 (nM)1584.89N/AN/ADetails
TerazosinPotassium voltage-gated channel subfamily H member 2IC 50 (nM)17782.79N/AN/ADetails
TerfenadinePotassium voltage-gated channel subfamily H member 2IC 50 (nM)213.8N/AN/ADetails
ThioridazinePotassium voltage-gated channel subfamily H member 2IC 50 (nM)95.5N/AN/ADetails
VerapamilPotassium voltage-gated channel subfamily H member 2IC 50 (nM)141.25N/AN/ADetails